Io Therapeutics, founded in Santa Ana, United States, and now headquartered in Houston, Texas, is a privately held biopharmaceutical company. The company's core mission is to discover and develop therapeutic compounds targeting cancers, neurodegenerative diseases, and autoimmune disorders. Their product pipeline includes retinoid and rexinoid small molecules such as IRX4204, IRX5183, and IRX4647, aimed at innovative treatments in immuno-oncology, autoimmune therapeutics, and neurotherapeutics.
Notable affiliated individuals include a distinguished board and management team with extensive experience in biopharmaceuticals. Io Therapeutics has secured several patents for their novel compounds and has presented their research at various scientific conferences. Their impact lies in pioneering new therapeutic avenues that address significant unmet medical needs, contributing to advancements in the treatment of complex diseases.
